Literature DB >> 8260253

Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials.

R H Begent1, K A Chester, T Connors, D Crowther, B Fox, E Griffiths, T A Hince, J A Ledermann, J G McVie, P Minor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8260253     DOI： 10.1016/0959-8049(93)90549-u

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Engineering recombinant antibodies for immunotherapy.

Authors:  D Neri; H Petrul; G Roncucci
Journal:  Cell Biophys       Date:  1995-08

2.  Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.

Authors:  E O Aboagye; S K Luthra; F Brady; K Poole; H Anderson; T Jones; A Boobis; S S Burtles; P Price
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

3.  Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.

Authors:  J L Casey; M P Napier; D J King; R B Pedley; L C Chaplin; N Weir; L Skelton; A J Green; L D Hope-Stone; G T Yarranton; R H J Begent
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.